Abstracts tagged "bone density and osteoporosis"

Abstract Number: 1875 • 2019 ACR/ARP Annual Meeting
Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study
David Kendler¹, Arkadi Chines ², Patricia Clark ³, Peter R. Ebeling ⁴, Michael McClung ⁵, Yumie Rhee ⁶, Shuang Huang ², Robert Kees Stad ⁷ and Nick Freemantle ⁸, ¹University of British Columbia, Vancouver, BC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³Hospital Infantil de Mexico Federico Gómez and National University of Mexico, Mexico City, Mexico, ⁴Monash University, Melbourne, Victoria, Australia, ⁵Oregon Osteoporosis Center, Portland, OR, ⁶Yonsei University College of Medicine, Seoul, Republic of Korea, ⁷Amgen Inc., Rotkreuz, Zug, Switzerland, ⁸University College London, London, England, United Kingdom
Background/Purpose: There are limited data on patients transitioning from denosumab (DMAb) to bisphosphonates (BPs). The Denosumab Adherence Preference Satisfaction (DAPS) study (NCT00518531) reported that alendronate…
Abstract Number: 59 • 2017 ACR/ARHP Annual Meeting
Abaloparatide, a Novel PTHrP Analog, Increased Bone Mass and Density at Cortical and Trabecular Sites in an Orchiectomized Rat Model of Male Osteoporosis
Heidi Chandler¹ and Gary Hattersley², ¹Research, Radius Health Inc, Waltham, MA, ²Radius Health, Inc., Waltham, MA
Background/Purpose: Male osteoporosis, a disease of reduced bone mass leading to an increased risk of fragility fractures, often results from androgen deficiency caused by hypogonadism…
Abstract Number: 2516 • 2017 ACR/ARHP Annual Meeting
Trabecular Bone Score As an Assessment Tool to Identify the Risk of Osteoporosis in Axial Spondyloarthritis: A Case-Control Study
Kwi Young Kang, Internal Medicine, Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: The trabecular bone score (TBS) is a novel tool used to evaluate bone microarchitecture. It is a textural index that evaluates pixel gray-level variations…
Abstract Number: 360 • 2016 ACR/ARHP Annual Meeting
Osteoporosis Prevalence in Lung Transplant Patients
Mireia Barceló-Bru¹, Sandra Farietta-Varela², Basilio Rodriguez-Díez¹, Ernesto Trallero-Araguás¹, Mireia López-Corbeto², Juan Jose De Agustin De Oro², Roxana Coras² and Agusti Sellas-Fernandez², ¹Rheumatology, Hospital Universitario Vall d´Hebron, Barcelona, Spain, ²Hospital Universitario Vall d´Hebron, Barcelona, Spain
Background/Purpose: Osteoporosis prevalence in lung transplantation candidates is between 16-21%. In the last years, the survival rate after lung transplantation has definitely improved, due to…
Abstract Number: 1561 • 2015 ACR/ARHP Annual Meeting
The Effect of TNF Blockers on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate
Doo-Ho Lim¹, Seokchan Hong², Soo Min Ahn², Byeongzu Ghang³, Wook Jang Seo⁴, Yong-Gil Kim¹, Chang-Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ⁴Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea
Background/Purpose: Osteoporosis is more frequently observed in patients with rheumatoid arthritis (RA) than in general population. Bisphosphonate (BP), which suppresses bone resorption by inhibiting osteoclast…
Abstract Number: 920 • 2014 ACR/ARHP Annual Meeting
Randomized Controlled Trial to Assess the Safety and Efficacy of Odanacatib in the Treatment of Men with Osteoporosis
Eric Orwoll¹, Silvano Adami², Neil Binkley³, Roland Chapurlat⁴, Bente Langdahl⁵, Steven Doleckyj⁶, Hilde Giezek⁷, Boyd Scott⁸ and Arthur Santora⁸, ¹Oregon Health and Science University, Portland, OR, ²Rheumatology Department, University of Verona, Verona, Italy, ³University of Wisconsin, Madison, WI, ⁴Pavillon F Rheumatology, Hopital Edouard Herriot, Lyon, France, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Belgium, Brussels, Belgium, ⁸Merck Sharp & Dohme Corp., Whitehouse Station, NJ
Background/Purpose Osteoporosis in men is an important clinical problem, associated with significant morbidity, mortality and societal expense. Men with osteoporosis represent between 20 and 25%…
Abstract Number: 727 • 2012 ACR/ARHP Annual Meeting
Effects of Odanacatib On BMD and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate
Roland Chapurlat¹, Sydney Bonnick², Tobias De Villiers³, Alberto Odio⁴, Santiago Palacios⁵, Boyd Scott⁶, Celine Le Bailly De Tilleghem⁷, Carolyn DaSilva⁶, Albert Leung⁸ and Deborah Gurner⁶, ¹Hôpital Edouard Herriot, Lyon, France, ²Director Osteoporosis Services, Cooper Clinic, Dallas, TX, ³Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, ⁴Alta California Medical Group, Simi Valley, CA, ⁵Instituto Palacios, Madrid, Spain, ⁶Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ⁷MSD Europe Inc., Brussels, Belgium, ⁸Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib (ODN) is a potent, orally-active cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN…
Abstract Number: 1981 • 2012 ACR/ARHP Annual Meeting
Low Body Mass Index, Medication Use and Social Factors Such As Smoking but Not Secondary Medical Disorders or Older Age May Be More Prevalent in Males with Low Bone Mineral Density
Vandana J. Vedanarayanan, Allison V. Jones and Vikas Majithia, Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS
Background/Purpose: Osteoporosis (OP) in Males is prevalent and frequently under-recognized. There are a number of known demographic factors such as age, race and BMI as…
Abstract Number: 1994 • 2012 ACR/ARHP Annual Meeting
The Influence of Percentage Body Fat On Bone Mineral Density in Thin Patients
Andrew Blanshard¹ and Marwan Bukhari², ¹Department of Rheumatology, Lancaster University, Lancaster, United Kingdom, ²Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Low Body Mass Index (BMI) is associated with low Bone Mineral Density (BMD) and subsequent risk of fragility fracture. Percentage body fat (%BF), which…
Abstract Number: 1959 • 2012 ACR/ARHP Annual Meeting
Low Fracture Incidence Is Maintained in Postmenopausal Women ≥75 Years with Osteoporosis with Long-Term Denosumab Treatment
Socrates Papapoulos¹, Michael McClung², Nathalie Franchimont³, Jonathan D. Adachi⁴, Henry G. Bone⁵, Claude-Laurent Benhamou⁶, Jordi Farrerons⁷, JC Gallagher⁸, Johan Halse⁹, Kurt Lippuner¹⁰, Salvatore Minisola¹¹, Ove Törring¹², Nadia Daizadeh³, Andrea Wang³, Rachel B. Wagman³ and Steven Boonen¹³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Oregon Osteoporosis Center, Portland, OR, ³Amgen Inc., Thousand Oaks, CA, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Michigan Bone and Mineral Clinic, Detroit, MI, ⁶Centre Hospitalier Régional d'Orléans, Orleans, France, ⁷Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ⁸Creighton University Medical Center, Omaha, NE, ⁹Osteoporoseklinikken, Oslo, Norway, ¹⁰Bern University Hospital, Bern, Switzerland, ¹¹Sapienza, Università di Roma, Rome, Italy, ¹²Karolinska Institutet Sodersjukhuset, Stockholm, Sweden, ¹³Leuven University, Leuven, Belgium
Background/Purpose: In the pivotal fracture trial, FREEDOM, denosumab increased bone mineral density (BMD) and reduced the incidence of new vertebral, nonvertebral, and hip fractures in…
Abstract Number: 1971 • 2012 ACR/ARHP Annual Meeting
Resolution of Effects On Bone Turnover Markers and Bone Mineral Density After Discontinuation of Long-Term Bisphosphonate Use
Kenneth G. Saag¹, Claude-Laurent Benhamou², Tobias De Villiers³, C. Conrad Johnston Jr.⁴, Bente Langdahl⁵, Andrew Denker⁶, Annpey Pong⁶, John P. McGinnis⁶, Elizabeth Rosenberg⁶ and Arthur Santora⁶, ¹Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ²Centre Hospitalier Régional d'Orléans, Orleans, France, ³Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Merck Sharp & Dohme Corp., Whitehouse Station, NJ
Background/Purpose: While bisphosphonates (BP) have been well studied in long-term trials of up to 4 years' duration, relatively less is known about the immediate consequences…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].